Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 11/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2588507 | 0.87 | MTOR (0.38) | LRRK2ROCK2GSK3BDYRK1AROCK1 | |
| SCHEMBL2594243 | 0.78 | KDM4E (0.46) | LRRK2ROCK2GSK3BDYRK1AKDM4E | |
| SCHEMBL2592086 | 0.76 | ROCK2 (0.40) | LRRK2ROCK2GSK3BDYRK1AROCK1 | |
| SCHEMBL2594853 | 0.70 | LRRK2 (0.42) | LRRK2GSK3BDYRK1AKDM4EKMT2A | |
| SCHEMBL2593480 | 0.69 | IRAK4 (0.41) | LRRK2ROCK2GSK3BDYRK1AROCK1 | |
| SCHEMBL2594202 | 0.68 | KDM4E (0.41) | KDM4EPIK3CAMTOR | |
| SCHEMBL1694725 | 0.65 | KDM4E (0.56) | ROCK2KDM4EKMT2A | |
| SCHEMBL21359417 | 0.64 | MCL1 (0.47) | ROCK2ROCK1 | |
| SCHEMBL2594655 | 0.64 | PIK3CA (0.48) | LRRK2ROCK2ROCK1PIK3CAMTOR | |
| SCHEMBL3506781 | 0.62 | AKT1 (0.48) | ROCK2ROCK1ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846935-B2 | Indazoles | GLAXOSMITHKLINE LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130053383-A1 | INDAZOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053383-A1 | INDAZOLES | IDH3A, CYP3A7, IDH3B | LRRK2 2947/4885ROCK2 1949/4885GSK3B 2146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.